New Zealand's E-cigarette Retail Growth Raises Concerns

Oct.06.2022
New Zealand's E-cigarette Retail Growth Raises Concerns
New Zealand sees a surge in vaping retailers, causing concern for CEO of the Asthma and Respiratory Foundation.

Letitia Harding, CEO of the Asthma and Respiratory Foundation New Zealand, has pointed out that the significant increase in the index of professional e-cigarette retailers in New Zealand over the past 12 months is a cause for concern.


As of February 2022, there are 666 registered professional e-cigarette retailers in New Zealand, and as of today, we now have 956. To put this in perspective, New Zealand has a total of 267 KFC and McDonald's restaurants. We have heard firsthand from the community that they are tired of e-cigarette shops popping up everywhere, with their products displayed in storefront windows," states Harding.


While regulations exist to oversee electronic cigarette stores, the foundation is concerned that these regulations are not being fully implemented and that retailers are taking advantage of the current environment to maximize their profits.


We don't need 934 specialized e-cigarette retailers. This means that e-cigarettes are easily accessible and readily available, which will only fuel the popularity of e-cigarettes among New Zealand teenagers," she said.


The foundation is particularly concerned about the widespread existence of "professional electronic cigarette retailers" that are being built within existing convenience stores. "This is a loophole that many retailers have been utilizing to sell more electronic cigarette products," she explained. "According to current regulations, only professional electronic cigarette retailers are allowed to sell the full range of electronic cigarette flavors.


The foundation believes that fundamentally changing the regulations surrounding tobacco products in smoke-free environments and amending the controlled products legislation is a timely opportunity to address the harm caused by electronic cigarette products. In the proposed legislation, the foundation is calling for stricter controls on e-cigarette retailers and a reduction in the nicotine content of e-cigarette products.


Dr. Stuart Jones, a respiratory advisor and consultant, stated that while this bill has changed the game for how New Zealand addresses the harms caused by tobacco cigarettes, there is still a need to address the widespread use of Electronic Nicotine Delivery Systems (ENDS) among young people.


We have too many young people who have become addicted to nicotine through the use of electronic cigarette products. We can no longer wait a few more years to establish better regulations regarding ENDS products, as the magnitude of this problem will only continue to grow. Reducing the nicotine content in electronic cigarette products needs to be treated as an urgent matter. We need retailers to be kept away from our school environments and we need better regulation of these retailers," he said.


Statement:


This article is a compilation of information from third-party sources and is intended for industry professionals for educational and exchange purposes.


This article does not represent the views of 2FIRSTS and 2FIRSTS is not able to confirm the truthfulness and accuracy of the content. The translation of this article is intended only for industry communication and research.


Due to limitations in translation proficiency, the article may not accurately reflect the original text. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan, or international issues and stances.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Grants MRTP Orders for 20 ZYN Nicotine Pouches
FDA Grants MRTP Orders for 20 ZYN Nicotine Pouches
The U.S. Food and Drug Administration (FDA) has issued modified risk granted orders to Swedish Match USA for 20 ZYN nicotine pouch products, allowing the already-authorized products to be marketed with a specific claim that using ZYN instead of cigarettes lowers the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis.
Jul.01
China Tobacco Hubei Industrial Patent Discloses Nicotine Tooth Patch for Fixed Oral Delivery
China Tobacco Hubei Industrial Patent Discloses Nicotine Tooth Patch for Fixed Oral Delivery
According to Chinese patent records, a “nicotine tooth patch” application filed by China Tobacco Hubei Industrial Corporation (CTHB) and Hubei Xinye Tobacco Sheet Development Co., Ltd. was published on May 19, 2026. The filing proposes a nicotine gel patch that adheres to the tooth surface, especially the lingual side, to reduce displacement, foreign-body sensation, and accidental swallowing risks associated with existing oral nicotine products.
Jun.10
From myblu to Zone: Imperial Brands Refocuses NGP Strategy in HY26
From myblu to Zone: Imperial Brands Refocuses NGP Strategy in HY26
mperial Brands’ HY26 results point to a more selective NGP transition. The company is using cash flow from traditional tobacco to fund targeted investments in modern oral nicotine, heated tobacco and reusable vaping systems. Its decision to exit the legacy myblu vaping business in the U.S., while expanding Zone nicotine pouches. In Europe, Imperial’s NGP growth is being driven by a multi-category portfolio including blu, Pulze and Zone/Skruf.
Special Report
May.12
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13
AP Questions FDA Rationale as Glas Fruit-Flavored Vapes Won Authorization Without Added Cessation Benefit
AP Questions FDA Rationale as Glas Fruit-Flavored Vapes Won Authorization Without Added Cessation Benefit
The U.S. Food and Drug Administration (FDA) recently authorized two fruit-flavored vaping products from Glas, but a newly released agency memo shows the products did not demonstrate greater smoking-cessation benefits than tobacco-flavored e-cigarettes. The Associated Press said the findings are likely to raise further questions about the FDA’s regulatory rationale and standards for flavored vaping products.
Jun.12
 Philip Morris Lowers Profit Outlook as Zyn Faces Competition and FDA Delays
Philip Morris Lowers Profit Outlook as Zyn Faces Competition and FDA Delays
According to Reuters, Philip Morris International (PMI) lowered its 2026 adjusted earnings-per-share forecast amid regulatory uncertainty around Zyn nicotine pouches, rising competition and shipment pressure in the U.S. market.
PMI
Jun.02